Renoprotective properties of pirfenidone in subtotally nephrectomized rats. - Wikidata - awgldk - TriplyDB

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

http://www.wikidata.org/entity/Q34087790

about

Management of fibrosis: the mesenchymal stromal cells breakthrough N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats Effects of Pirfenidone and Collagen-Polyvinylpyrrolidone on Macroscopic and Microscopic Changes, TGF-β1 Expression, and Collagen Deposition in an Experimental Model of Tracheal Wound Healing.Therapeutic targets for treating fibrotic kidney diseases Renal interstitial fibrosis: mechanisms and evaluation.Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis.Immune and inflammatory role in renal disease.Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Pathophysiology of the aging kidney and therapeutic interventions.Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.Molecular targets for treatment of kidney fibrosis.The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.New renal drug development to face chronic renal disease.Antioxidant treatment reverts increased arterial Basal tone and oxidative stress in nephrectomized (5/6) hypertensive rats.Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats.Renal hypoxia in kidney disease: Cause or consequence?Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.

P2860

Q26827231-F272D3C3-1CA9-4EFA-9075-A9E0A02F6E26 Q27008887-DA1504B4-827E-41A3-8B1E-B25452BF26A6 Q28468333-BF2AAAF0-BC34-493A-AF9C-E1E4C208123A Q28484321-386EAF9A-0979-459A-9816-2C9B1801A8E1 Q28536610-07D7C12C-9211-40B1-B3F2-577550022FA8 Q33726417-28C09D58-5C97-4477-8A5B-3315D61F711B Q35079607-A4A07DF3-CB53-4E92-A573-29E577C59E18 Q35967489-B137E567-DC81-480E-A168-70F6C5B81F54 Q36288420-950F19CC-9A09-4B1C-8A01-CE17E4876DF2 Q36589609-7999594B-BEDE-47F9-A213-FBF324364345 Q37243199-3576D2B6-D84C-411F-B029-B486119003A4 Q37708036-A7A7681F-B5B5-430A-9EE5-1B053553D1CC Q37904098-8308C112-444D-4A45-936D-2B4BBB78D8A1 Q38053074-EF491FD1-AC73-4EE1-BCD1-EAF6CF08F928 Q38054089-F98B6964-310E-4304-BDB2-4F8F7BE44649 Q38062404-E287A14C-92EC-4282-8C11-46ABA9BFF302 Q38224257-27DCC464-32A1-4AE0-AC6A-1D716F8BE535 Q38246640-99F99CF4-A90B-42B6-A295-E70A86FD7AB2 Q39375774-C64B1CC5-9A21-4836-8FD3-5AE517BC6E3C Q44328029-B281A985-B57A-49B7-A699-E4E4CB7F5BD6 Q49842384-C61DB189-8BB2-4CEB-A175-1F1C00D040DE Q51728385-A791D284-35FA-456F-8F91-71067D2262B3 Q54481748-B984BEE4-F41D-4BAD-B180-98F4EFEE8306

P2860

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

http://www.wikidata.org/entity/Q34087790

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@ast

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@en

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@nl

type

label

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@ast

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@en

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@nl

prefLabel

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@ast

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@en

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@nl

P1433

Q34087790-669B4E91-E168-4247-B139-0EFE37794EB5

P1476

Q34087790-2963CA9F-330D-42D5-AC00-EC6FA588C241

P2093

Q34087790-03F4D1F4-81B0-4AC7-96B1-22C22D16B8ED

Q34087790-17D0F84C-5719-4DA4-8D1D-63FF6E039B32

Q34087790-32605BD7-7A8D-4585-B327-0644DD5C2EB8

Q34087790-4902834E-0D5D-45D0-911B-AD0F0E32C593

Q34087790-51AAB04F-A22A-4505-AD25-25D77824D0CB

Q34087790-53BC498B-35E2-4AC8-B8B2-BBC4745139FA

Q34087790-6D7D648A-9B8F-4EE3-A4CC-4311A752262C

Q34087790-7199114A-9BF2-4257-8450-4F2F67B3B362

Q34087790-C59739E0-D179-47D5-A993-11E8E9ED800B

P304

Q34087790-277A6F89-9298-450B-8964-EE69A5CE4418

P31

Q34087790-4CC557EF-8BB2-45B4-A131-BE55E0E619AF

P356

Q34087790-175D1C7F-7A02-4193-A11C-5AF38E8AE180

P407

Q34087790-A029C5BB-7D10-4CDD-BD59-29406D06BC61

P433

Q34087790-BA989496-705B-4E18-BFD8-5EA538B9AF38

P478

Q34087790-381967C8-1BDB-4E2A-B74C-65669D056CD9

P577

Q34087790-648E7F5E-B84C-4A5E-96AA-832978042A77

P698

Q34087790-9B42215C-E7D9-48A9-B8D8-7398D886E9A8

P356

J.EJPHAR.2009.12.011

P1433

European Journal of Pharmacology

P1476

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

@en

P2093

Akira Fujimori

http://www.w3.org/2001/XMLSchema#string

Akira Tanokura

http://www.w3.org/2001/XMLSchema#string

Hidenori Nakajima

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Itoh

http://www.w3.org/2001/XMLSchema#string

Koji Takakuta

http://www.w3.org/2001/XMLSchema#string

Masamichi Okada

http://www.w3.org/2001/XMLSchema#string

Masanori Yamamoto

http://www.w3.org/2001/XMLSchema#string

Toshihiro Chikanishi

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Iwatsuki

http://www.w3.org/2001/XMLSchema#string

P304

118-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPHAR.2009.12.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

629

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20006961

http://www.w3.org/2001/XMLSchema#string